Cara Therapeutics Agrees to Merge With Tvardi Therapeutics-March 2024-www.financetom.com

Cara Therapeutics Agrees to Merge With Tvardi Therapeutics

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Cara Therapeutics Agrees to Merge With Tvardi Therapeutics

Dec 18, 2024 5:06 AM

07:31 AM EST, 12/18/2024 (MT Newswires) -- Cara Therapeutics ( CARA ) and Tvardi Therapeutics said Wednesday they have signed an agreement to merge in an all-stock deal.

Under the terms of the agreement, Tvardi will merge with a subsidiary of Cara Therapeutics ( CARA ). When the merger closes, Cara Therapeutics ( CARA ) shareholders will own approximately 17% of the combined company while Tvardi Therapeutics' investors are expected to own the remaining 83%.

Financial terms were not disclosed.

Upon deal completion, the combined company is expected to operate under the name Tvardi Therapeutics and trade on Nasdaq under the ticker symbol, "TVRD."

Previous page： Once a beacon of stability, Vietnam to name third president in a year Next page： Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Once a beacon of stability, Vietnam to name third president in a year

Mar 22, 2024

HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...

Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug

Mar 22, 2024

05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...

Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut

Mar 22, 2024

Japan's union group Rengo announces biggest wage hikes on record

Mar 22, 2024

TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...